

**Steven H. Reynolds, D.O.**  
Collaborative Neuroscience Network, Inc.  
12772 Valley View Street, Suite 3  
Garden Grove, CA 92845  
Tel. (714) 799-7799

**CONTACT INFORMATION:**

Site Selection and Information:  
Bobbie Theodore, Site Liaison  
Tel. (866) 669-0234  
Fax (208) 575-3169  
Email: clinicaltrials@btheodore.com

**AFFILIATIONS:**

Collaborative Neuroscience Network, Inc.  
19401 S. Vermont Avenue, Suite F-100  
Torrance, CA 90502

Collaborative Neuroscience Network, Inc.  
2600 Redondo Avenue, Suite 500  
Long Beach, CA 90806

Ocean View Psychiatric Health Facility  
2600 Redondo Avenue, Suite 500  
Long Beach, CA 90806

**EDUCATION:**

College:  
1984, Degree: Microbiology  
San Diego State University

Medical School:  
1992, Degree: D.O.  
Midwestern University, Chicago College of Osteopathic Medicine

**RESIDENCIES:**

Residency in Family Medicine  
Residency, 1992- June 1995  
Chief Resident, Inpatient Medicine, 1995

**CERTIFICATION:**

Board Certified, American Board of Family Practice  
American College of Occupational and Environmental Medicine (ACOEM)

**LICENSURE:**

California Medical License 20A6475  
DEA BR3920801

**PROFESSIONAL EXPERIENCE:**

*Investigator*, Collaborative Neuroscience Network, Inc. 2010 – Present

*Private Practice*, Family Health Care of Long Beach (2008 – Present)

*Medical Review Officers*, ACOEM Certified at Central Drug Systems (2009)

*Active Staff*, Long Beach Memorial Medical Center, Miller Children’s Hospital  
and Memorial Women’s Hospital

*Associate Professor*, University of Irvine College of Medicine  
(Department of Family Medicine)

*Teaching Faculty*, Long Beach Memorial Family Medicine Residency

*Police Surgeon and consultant*, City of Long Beach Police Department

**Continued Experience:**

Marina Family Medicine 2006 – 2008

Seal Beach Family Medical Group 1995 – 2006

*Contract Physician* for Long Beach Memorial Urgent Care 1995- 1996

*Contract Physician* for Manhattan Beach Care Station, 1994 – 1995

*Contract Physician* for Los Alamitos Family Medical Group, 1995

**INVESTIGATOR EXPERIENCE:**

Alzheimer’s Disease • Bipolar Disorder • Diabetic Neuropathy  
Depression • Epilepsy • Migraine • Osteoarthritis • Schizophrenia

**TREATMENT EXPERIENCE:**

Acid Reflux • Constipation • Depression • Dislipidemia • Healthy Adult • High Blood Pressure • Hepatitis C • High Cholesterol • Hypercholesterolemia • Hypogonadism  
Hypertension • Influenza • Irritable Bowel Syndrome • Male/Female Hormone • Obesity  
Opioid-Induced Constipation • Pain • Type 2 Diabetes • Vaccine

**CLINICAL TRIAL EXPERIENCE:**

*Alzheimer's Disease*

A Phase III Multi-center, Randomized, Placebo-Controlled, Double-Blind, Twelve-Month Safety and Efficacy Study Evaluating XXX in Patients with Mild-to-Moderate Alzheimer's Disease XXX

A 24 Week Open-Label Extension to Study XXX

A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-center Study Comparing the Effects of XXX vs. XXX on Activities of Daily Living and Cognition in Patients with Severe Dementia of the Alzheimer's Type (ACTION)

A Phase IIa, Multi-center, Randomized, Double-Blind, Placebo Controlled Study to Investigate Efficacy and Safety of XXX in Patients with Mild to Moderate Alzheimer's disease

A Phase III, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of XXX in Patients with Mild to Moderate Alzheimer's Disease who are Apolipoprotein E 4 Non-Carriers AND A Phase III, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of XXX in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E4 Carriers

A Phase III, Multi-center, Parallel-Group, Long Term Safety and Tolerability Treatment Trial of XXX in Subjects with Alzheimer's Disease Who Participated in Study XXX or in Study XXX

A 28-Week Open Label Extension Study Evaluating the Safety and Tolerability of XXX in Subjects with Mild Cognitive Impairment

A Randomized Controlled Trial to Assess the Efficacy of a Medical Food in Patients with Mild to Moderate Alzheimer's Disease using Alzheimer's Disease Medication

**CLINICAL TRIAL EXPERIENCE (continued):**

A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of XXX in the Treatment of Patients with Prodromal Alzheimer's Disease

***Bipolar Disorder***

A Long-Term Open-Label Study of the Safety and Tolerability of XXX in Patients with Bipolar I Disorder

A 24-Week, Flexible-Dose, Open-Label Extension Study of XXX for the Treatment of Bipolar I Depression

A 6-Month, Open-Label, Flexible-Dosage (150-200 mg/day) Extension Study of the Safety and Efficacy of XXX Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

***Depression***

A Double-Blind, Randomized, Multi-center, Placebo-Controlled, Relapse Prevention Study with XXX in Out-Patient Adults with Major Depressive Disorder

An 8-week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-center Study of the Efficacy and Safety of XXX Sublingual Tablets Administered Once Daily in Patients with Major Depressive Disorder (MDD)

A Double-Blind, Placebo-Controlled Study of XXX as Adjunctive Therapy in Major Depressive Disorder A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of XXX Treatment (150 and 200 mg/day) as Adjunctive Therapy in Adults with Major Depression Associated With Bipolar I Disorder

A Phase III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 20 mg) of XXX in Acute Treatment of Adults with Major Depressive Disorder

A Multi-center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Long-Term Safety and Tolerability Study of XXX as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate response to Antidepressant Therapy

A Multi-center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of XXX as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy

**CLINICAL TRIAL EXPERIENCE (continued):**

A Phase IIA, Double Blind, Placebo-Controlled Study of the Efficacy and Safety of XXX Augmentation of Antidepressant Therapy in Major Depression

A Phase III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 20 mg) of XXX in Acute Treatment of Adults with Major Depressive Disorder

A Phase IIIb, 12-Week, Double-Blind, Placebo-Controlled, Multi-center Study Evaluating the Safety and Efficacy of XXX 1MG Bid for Smoking Cessation in Subjects with Depression

A Phase IIA, Double Blind, Placebo-Controlled Study of the Efficacy and Safety of XXX Augmentation of Antidepressant Therapy in Major Depression

***Epilepsy***

A Phase III Study that is Analyzing the Effectiveness and Safety of XXX Injections for Patients with Epilepsy that Receive Antiepileptic Drugs, but Still Experience Acute Repetitive Seizures (Bouts or Clusters of Seizures) that Require Treatment

A Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of XXX Monotherapy in Subjects with Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs to be Managed by XXX to Evaluate the Safety and Efficacy of an Investigational Product as Monotherapy in Subjects with Partial Epilepsy Unresponsive to Current Antiepileptic Drugs (AED) in Comparison to Historical- Pseudo -Placebo Control Groups

A Double-Blind, Randomized, Historical-Controlled, Multi-Center Efficacy and Safety Study of XXX as Monotherapy in Patients With Refractory Partial Seizures & An Open-Label Multi-Center Extension Study to Determine Long Term Safety and Efficacy of XXX as Monotherapy in Patients With Partial Seizures

***Pain***

A Randomized, Placebo-Controlled Trial of XXX Added to Nonsteroidal Anti-inflammatory Drugs in Patients with Knee Pain due to Osteoarthritis who have had Suboptimal Response to Nonsteroidal Anti-inflammatory Drug Treatment

A Phase III, Open Label Long Term Safety Study: An Open-Label Study to Assess the Long-Term Safety of XXX in Patients with Opioid-Induced Constipation (OIC)

A Randomized, Double-Blind, Parallel-Group Study of XXX vs. Oxycodone (IR) for the Treatment of Acute Low Back Pain  
A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of XXX in Adult Migraineurs

**CLINICAL TRIAL EXPERIENCE (continued):**

A Randomized, Placebo-Controlled Trial of XXX Added to XXX Anti-inflammatory Drugs in Patients with Knee Pain due to Osteoarthritis who have had Suboptimal Response to Nonsteroidal Anti-inflammatory Drug Treatment

A Randomized, Multi-center, Double-Blind, Parallel-Group Trial with Controlled Adjustment of Dose Assessing the Analgesic Efficacy and Safety of a New Analgesic Compared with Placebo in Subjects with Painful Diabetic Peripheral Neuropathy

A Phase IIb Repeat Dosing Clinical Trial of XXX in Subjects with Moderately Severe Diabetic Neuropathy

***Schizophrenia***

A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of XXX a 3-Month Formulation in Subjects with Schizophrenia

An Evaluation of the Long-Term Safety, Tolerability and Pharmacokinetics of XXX in Patients with Schizophrenia

A Phase IIa, Multi-center, Double-Blind, Randomized, Parallel Group, 4-Week Inpatient Treatment Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Two Fixed Doses of XXX Compared to Placebo, Using XXX as an Active Control, in the Treatment of Acute Exacerbation of Schizophrenia

A Long-Term Safety, Tolerability, and Effectiveness of XXX in Subjects with Schizophrenia or Schizoaffective Disorder: A Randomized, Active Comparator-Controlled Trial

A Long-Term, Open-Label, Multicenter Study of XXX Compared to Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia

A 17-Week, Phase II, Multi-center, Randomized, Double-Blind Study of Treatment with XXX Combined with Standard of Care Compared to placebo Combined with Standard of Care in the Treatment of Patients with DSM-IV-TR Schizophrenia with Prominent Negative Symptoms

A 38-Week, Multi-center, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of XXX as Maintenance Treatment

A Multi-center, Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of XXX in Patients with Schizophrenia

**CLINICAL TRIAL EXPERIENCE (continued):**

A Randomized Phase II, Double-Blind, Placebo-Controlled, Multi-center Study of XXX as Add-on Therapy in Outpatients with Persistent Negative Symptoms of Schizophrenia Treated with A Stable Dose of a Second Generation Antipsychotic

A Phase II, Double-Blind Placebo-Controlled Randomized Withdrawal, Multi-center, Safety and Efficacy Study in Adults with Predominant Negative Symptoms and Clinically Stable Schizophrenia who are Taking Stable Dose of Antipsychotic Medication

***Other***

A Phase II, Double-Blind, Placebo-Controlled, Randomized study to assess the Efficacy, Safety, and Tolerability of following Multiple Intravenous Doses in Hypercholesterolemic subjects on maximum dose of XXX or XXX

**PROFESSIONAL ORGANIZATIONS/MEMBERSHIPS:**

**Member of American Academy of Family Physicians**

**California Academy of Family Physicians, Long Beach Chapter**

**American College of Occupational and Environmental Medicine (ACOEM)**

**American Osteopathic Association**

**Honorary member of Long Beach Police Officers Association**

**Memorial Healthcare IPA**

**ABSTRACTS AND PUBLICATIONS:**

“Plasma Sialyltransferase, Total and Iso-Enzyme Activity in the Diagnosis of Colon Cancer” Journal of Clinical Biochemistry, (1) 46-48 (1982) and XI International Congress of Clinical Chemistry

Clinical Researcher, University of California at San Diego, Study entitled: “Rates of Decline in Pulmonary Function Over a 20 Year Period” done on San Diego Firemen

“Development and Administration of an HIV/AIDS Screening Program” presented by invitation of the American Public Health Association at the 114<sup>th</sup> Annual Meeting, Sept 28 – Oct 2, 1986 in Las Vegas, Nevada